Ofatumumab Interruption Results in Disease Reactivation: A Case Report

"Our case highlights a real-world clinical scenario that may have clinical implications for people with #MultipleSclerosis treated with #ofatumumab, an anti-CD20 therapy with a shorter half-life, after stopping treatment or attempting to become pregnant." doi.org/10.7224/1537...

🆕New research online!

📊In this single‑centre retrospective study, #ofatumumab showed faster and greater benefit in MuSK‑positive vs AChR‑positive #MyastheniaGravis.

💡Findings suggest subtype‑specific treatment strategies may be needed: journals.sagepub.com/doi/full/10....

Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells Key PointsComplement-fixing CD20 mAbs deposit C3d on lymphoma cells; this neo-antigen can be selectively targeted to boost therapeutic efficacy.In B-cell l

Targeting CD3d is a feasible option after CD20 lost due to #ofatumumab in #CLL in a pts-derived xenograft model

ashpublications.org/blood/articl...

#Obinutuzumab and #Ofatumumab are More Effective Than Rituximab in the Treatment of #MembranousNephropathy Patients With Anti-Rituximab Antibodies

#VisualAbstract by @priti899

www.kireports.org/ar...